CytoMed Therapeutics (GDTC) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CytoMed Therapeutics (GDTC) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 59.8% versus a loss of 86.1%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $9.0 million), about 1.1 times the size. Radiopharm Theranostics converts more of its revenue into profit, with a net margin of -1055.3% versus -1227.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDTC | RADX |
|---|---|---|
| Share price | $0.755 | $0.6304 |
| Market cap | $9.01M | $9.90M |
| 1-day change | -2.33% | -9.71% |
| YTD return | -43.45% | -87.92% |
| 1-year return | -59.84% | -86.15% |
| EPS (TTM) | $-0.23 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $252.26K | $3.63M |
| Revenue growth (YoY) | +395.88% | +1114.27% |
| Net income (latest FY) | $-3.10M | $-38.34M |
| Gross margin | — | 1.08% |
| Operating margin | — | -1050.63% |
| Net margin | -1227.07% | -1055.27% |
| 52-week high | $2.12 | $16.25 |
| 52-week low | $0.68 | $0.63 |
| Distance from 52-week high | -64.39% | -96.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +450.99% | +2595.11% |
| Average volume | 15.69K | 55.23K |
| Shares outstanding | 11.93M | 15.70M |
| Employees | 42 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GDTC has outperformed RADX by 26.3 percentage points over the past year.
- Radiopharm Theranostics is more profitable, keeping -1055.3 cents of every revenue dollar as net income versus -1227.1 cents for CytoMed Therapeutics.
- Radiopharm Theranostics grew revenue faster in its latest fiscal year (+1114.27% vs +395.88%).
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
GDTC vs RADX FAQ
Which is bigger, CytoMed Therapeutics or Radiopharm Theranostics?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $9.01M for CytoMed Therapeutics (GDTC).
Which stock has performed better over the past year, GDTC or RADX?
GDTC returned -59.84% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are CytoMed Therapeutics and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.